A Phase 1 interventional study of CJ-023,423 and placebo in Osteoarthritis, sponsored by Pfizer. Completed at 11 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2008-03-24.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing naproxen in Osteoarthritis — none open to participants now, 1 under way, none of them phase 3. Naproxen · Osteoarthritis.
Among the 14 studies testing naproxen in Osteoarthritis, this one is the 3rd largest by planned enrollment, is one of 2 that started in 2006, is one of 5 in phase 1, and was the 3rd registered.
2,978 studies on the registry are indexed under Osteoarthritis; 437 are open to participants now.
Browse Osteoarthritis studies →None of the 14 studies testing naproxen in Osteoarthritis is open now. The open studies under Osteoarthritis, anywhere →
Naproxen: first FDA approval 1976 (NAPROSYN). What it is approved for, and how studies give it, is on its page →
Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 340 is above the median of 80 across 2,241 interventional studies indexed under Osteoarthritis.
Median enrollment 103 across the 14 interventional studies. Of the 12 that completed or were terminated, 1 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 14 have an industry lead sponsor. The 9 most frequent:
Pfizer is the lead sponsor of 3,338 studies on the registry; 147 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 393 (65%) have results posted.
39 studies in Osteoarthritis by Pfizer: 2 open now, 2 under way, 2 of them phase 3. Of 36 finished, 20 (56%) have results posted.
Among the 39 studies in Osteoarthritis by Pfizer, this one is the 17th largest by planned enrollment of the 37 interventional ones that give a count, is one of 6 that started in 2006, is one of 8 in phase 1, and was the 3rd registered.
Pfizer’s Osteoarthritis studies by the year they started, since 2003.
1 of the studies testing naproxen in Osteoarthritis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05430230Northwestern UniversityStudy of Nonsteroidal Anti-inflammatory Drugs in People With Painful Knee Osteoarthritis | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies testing naproxen in Osteoarthritis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 39 in Osteoarthritis:
This tab as a report to print or save as PDF → With an account.
CJ-023,423 is a new medication being developed as an anti-inflammatory agent for the treatment of the signs and symptoms of osteoarthritis (OA). The purpose of this study is to evaluate whether patients treated with CJ-023,423 for 7 days (14 doses) have fewer gastrointestinal ulcers compared to patients treated with naproxen and placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: placebo
75 mg BID
Drug: naproxen
Drug: CJ-023,423
75 mg BID
placebo
naproxen
The primary endpoint is the presence of gastroduodenal ulcers in each subject, as determined by a UGI endoscopy at the end of the treatment
Time frame: 7 days
Incidence of treatment-emergent, all-causality GI body system adverse events
Time frame: Duration of trial
Severity of Dyspepsia Assessment (SODA)
Time frame: Duration of trial
Post treatment gastric, duodenal and gastroduodenal endoscopic scores (according to the mucosal grading scale). The gastroduodenal score is defined as the higher of the gastric and duodenal scores.
Time frame: Duration of trial
Incidence of any gastric ulcer
Time frame: Duration of trial
Incidence of any duodenal ulcer
Time frame: Duration of trial
Incidence of any gastroduodenal erosion or ulcer
Time frame: Duration of trial
Incidence of any gastric erosion or ulcer
Time frame: Duration of trial
Incidence of any duodenal erosion or ulcer
Time frame: Duration of trial
Incidence of any esophageal ulcer using the traditional grading method of: normal, erosion or ulcer
Time frame: Duration of trial
Incidence of any esophageal ulcer or erosion using the LA classification: esophageal ulcers and erosions method with a Grade A, B, C, or D)
Time frame: Duration of trial
Number of gastroduodenal ulcers in each subject
Time frame: Duration of trial
The record gives a start of Nov 2006 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Grapiprant · Naproxen